Prevention of Muscle Wasting by CRISPR/Cas9-mediated Disruption of Myostatin In Vivo

Mol Ther. 2016 Nov;24(11):1889-1891. doi: 10.1038/mt.2016.192.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CRISPR-Cas Systems*
  • Clustered Regularly Interspaced Short Palindromic Repeats
  • Gene Editing*
  • Muscle, Skeletal / physiopathology
  • Myostatin / metabolism*
  • Wasting Syndrome / genetics
  • Wasting Syndrome / therapy

Substances

  • Myostatin